Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib DDI Study with Digoxin and Rosuvastatin in Healthy Subjects
NCT06677957Phase 1Completed
- Sponsor
- Genentech
- Start
- Nov 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of divarasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and solid tumor, sponsored by Genentech. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve from Hour 0 to Last Measurable Concentration and 2 more. Started Nov 2024; status: completed.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT06677957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06677957.